Proposed regulation on orphan drug reimbursement ignites German pharma industry
This article was originally published in SRA
Executive Summary
A recent Decision by the German joint federal committee (G-BA) to revise existing regulations on the procedure for reimbursing orphan drugs has been slated by the research-based pharmaceutical industry. Prior to obtaining reimbursement from the statutory health insurance funds for particular high-cost preparations used in the treatment of specific, severe illnesses, the presiding doctor must seek a second opinion.